The treatment, designated as a breakthrough therapy by the FDA, supports patients with symptomatic tenosynovial giant cell tumors that didn’t respond to surgery.
Surgery is the primary treatment option, but some patients are not eligible for surgery or have tumors reappear after surgery.
Turalio, made by Basking Ridge, N.J.-based Daiichi Sankyo, comes with a warning about the risk of serious liver toxicity.
More articles on pharmacy:
Pfizer to merge off-patent business with Mylan
Senate panel advances drug-pricing legislation
Average chief pharmacy officer salary by state
